Sage Journals: Discover world-class research

Abstract

Objectives

IgA antiphospholipid antibodies (aPL) are prevalent in systemic lupus erythematosus (SLE) patients of African American, Afro-Caribbean and South African origin. Nevertheless, data from North Africa are lacking, and most studies use manufacturer-suggested cut-offs based on Caucasian controls. Therefore, we compared aPL isotypes in Sudanese and Swedish SLE patients using nation-based cut-offs.

Methods

Consecutive SLE patients and age- and sex-matched controls from Sudan (N = 115/106) and Sweden (N = 340/318) were included. All patients fulfilled the 1982 American College of Rheumatology SLE classification criteria. Antiphospholipid syndrome–related events were obtained from patients’ records. IgA/G/M anticardiolipin and anti-β₂ glycoprotein I (β₂GPI) were analysed with two independent assays. IgA anti-β₂GPI domain 1 (D1) was also investigated. Manufacturers’ cut-offs and the 95th and 99th percentile cut-offs based on national controls were used.

Results

Sudanese patients and controls had higher levels and were more often positive for IgA aPL than Swedes when using manufacturers’ cut-offs. In contrast, using national cut-offs, the increase in IgA aPL among Sudanese patients was lost. Occurrence of IgA anti-D1 did not differ between the countries. Venous thromboses were less common among Sudanese patients and did not associate with aPL. No clinical associations were observed with IgA anti-β₂GPI in Sudanese patients. Thromboses in Swedes were associated with IgG/M aPL. Fetal loss was associated with aPL in both cohorts.

Conclusions

IgA anti-β₂GPI prevalence was higher among Sudanese compared to Swedish patients when manufacturers’ cut-offs were used. This situation was reversed when applying national cut-offs. Anti-D1 was not increased in Sudanese patients. Previous studies on populations of African origin, which demonstrate a high prevalence of IgA aPL positivity, should be re-evaluated using a similar cut-off approach.

Keywords

Systemic lupus erythematosus Sudan Africa Sweden antiphospholipid antibodies IgA anti-β2-glycoprotein I

Introduction

Antiphospholipid antibodies (aPL) are present in 20–30% of systemic lupus erythematosus (SLE) patients,¹ where IgA anti-β₂ glycoprotein I (β₂GPI) is reported to be a highly frequent isotype.^2–6 Only IgG and IgM anticardiolipin (aCL) and anti-β₂GPI are included in the 2006 revised Sapporo classification criteria for antiphospholipid syndrome (APS),⁷ whereas IgA aPL were added as laboratory parameters to the 2012 Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR)⁸ as well as the recent European League Against Rheumatism EULAR/ACR SLE classification criteria.⁹ The role of IgA aPL as a risk factor for thrombosis and adverse pregnancy outcomes in SLE remains inconclusive. A positive association with APS-related events was demonstrated in several studies for both IgA aCL²,³,¹⁰ as well as IgA anti-β₂GPI.²,⁴,^11–13 However, other investigators could not confirm these associations.³,¹⁰,¹⁴,¹⁵ Interpretation of data provided by previous studies on aPL in general and IgA aPL in particular and the relationship to APS features is rather complex. The fact that different study designs, immunological assays and cut-offs were used in these studies imposes more challenges in determining the true prevalence and clinical significance of aPL among SLE patients in different populations. Insufficient standardization of IgA aPL assays contributes to this enigma, heterogeneity was evident when comparing different diagnostic kits.^16–18 In addition, the frequent co-occurrence of other isotypes with IgA makes it even more troublesome to ascertain the individual role of IgA aPL in SLE.

Data are limited with regard to the prevalence of aPL isotypes, including IgA, and their clinical importance among SLE populations of African origin, with utterly deficient studies among populations living in Africa. According to the current literature, IgA aPL are described to be the most prevalent and clinically significant isotypes in SLE patients of African ancestry. Previous studies reported highly prevalent IgA anti-β₂GPI among African American SLE patients with associations with thrombosis and/or other APS-related events.²,⁴,¹⁹ In an earlier study of 100 black South African SLE patients, IgA aCL was found to be the most prevalent isotype, where both IgA aCL and IgA anti-β₂GPI were significantly associated with thrombosis.²⁰ In all of these studies conducted in populations of African origin, determination of cut-offs for aPL positivity was based on the assay manufacturers’ recommendation, or on values calculated according to levels in healthy controls using parametric statistical methods but where characteristics of the reference groups were not specified. Since distribution of aPL is not Gaussian, it is generally recommended to calculate aPL cut-offs using non-parametric statistics.⁷,²¹

The aim of this study was to determine the prevalence and clinical significance of the different aPL isotypes, with special emphasis on IgA. We also investigated IgA anti-β₂GPI domain 1 (anti-D1) using conventional as well as nationally adjusted non-parametric cut-offs.

Methods

Participants

This cross-sectional study included 115 Sudanese and 340 Swedish SLE patients. Serum samples were available from 93 Sudanese and 333 and Swedish SLE patients as well as from 106 healthy and 297 population-based non-SLE controls, respectively. All controls were matched for age and sex to the respective patient groups. The lack of serum from some Sudanese patients was entirely due to technical reasons without selection bias. All SLE patients fulfilled the 1982 revised (ACR) criteria.²² A detailed description of cohorts was specified in our previous publication.²³ Clinical comparisons were first performed between the full cohorts. Due to the highly significant difference in age and disease duration, where Swedish patients were older with longer SLE duration, comparisons were also performed between nested cohorts matched for age and disease duration, including 88 Sudanese and 88 Swedish patients, in agreement with our previous study.²³ Clinical information including APS-related events was obtained from patients’ hospital records. These included a history of thrombotic events (venous: deep venous thrombosis and pulmonary embolism; and arterial: cerebrovascular accidents, myocardial infarction and peripheral tissue loss as described in the SLICC Damage Index (SDI)),²⁴ obstetric events (early and late miscarriage, intrauterine fetal demise (IUFD) and stillbirths) and cardiovascular (CVS) events as defined by the SDI.²⁴ The occurrence of thrombocytopaenia at study inclusion for Swedish patients and a history of immune thrombocytopaenic purpura (ITP) for Sudanese patients were also investigated for aPL occurrence.

All participants gave written informed consent, and their inclusion was in accordance with the Declaration of Helsinki. Approval was obtained from Ethical Committees of the study recruitment hospitals in Sudan (11 April 2011 and 25 May 2011) and Sweden (03-556; 16 December 2003).

Immunological testing

Quantification of aCL and anti-β₂GPI isotypes was performed using two assays: the EliA system based on fluorescence enzyme immunoassay (FEIA) on a Phadia 2500 instrument (Thermo Fisher Scientific, Uppsala, Sweden) according to the manufacturer’s instructions, and the Aptiva system based on a particle-based multi-analyte technology (PMAT; Inova Diagnostics, San Diego, CA). IgA anti-D1 was analysed using modified a QUANTA Flash β₂GPI-D1 chemiluminescence assay (BIO-FLASH; Inova Diagnostics). Specific analysis of the IgA isotype against D1 was performed in parallel with a previous study where a high prevalence of IgA anti-β₂GPI was observed during apparently normal pregnancies in Sudan, as previously described.²⁵ Lupus anticoagulant (LA) was not included in this study due to difficulties in conforming to sample handling recommendations for LA testing in Sudanese SLE patients.²⁶

FEIA analyses were performed on different occasions in Sudanese and Swedish subjects, whereas PMAT and IgA anti-D1 analyses were performed in parallel. However, in all cases, analyses of patients and national controls were performed in parallel.

The number of patients who had laboratory data for each immunological assay is shown in Table 2. All controls from both countries had aPL results using the FEIA, while only 102 Sudanese and 163 Swedish subjects had available aPL data using PMAT.

Statistical analysis

For comparisons between quantitative variables, the Mann–Whitney U-test was used, whereas the chi-square test was used to test for differences between categorical variables, with Fisher’s exact test applied when appropriate.

Three cut-offs were identified: the manufacturers’ suggested values (same for Sudanese and Swedish patients) and the 95th and 99th percentiles of the respective national controls. Non-parametric statistics were used to identify national cut-offs, since all aPL levels, irrespective of assay used, were not normally distributed, as tested by the Shapiro–Wilk test in controls (data not shown). The 99th national cut-offs were not used in the clinical association analyses, as the small number of Sudanese controls makes this cut-off uncertain. Data comparing the prevalence of aPL using the 99th percentile are shown with and without the exclusion of outliers using the modified Dixon D/R method by Reed.²⁷,²⁸

All statistical analyses including cut-off determination were conducted using JMP (SAS Institute, Cary, NC). p-Values <0.05 were considered significant.

Results

Demographics and clinical comparisons

Comparing APS-related events in the full cohorts, Sudanese SLE patients had a lower prevalence of venous thrombosis (7% vs, 15%; p = 0.03) compared to Swedish patients (Table 1). In agreement with our previous publication, Sudanese patients had a higher female preponderance and shorter disease duration compared to Swedish patients.²³ In the cohorts matched for age and disease duration, the occurrence of thrombosis or fetal loss did not differ between Sudanese and Swedish patients (Table 1).

Table 1.

Demographics and APS-related events in the investigated SLE patients.

	Sudan all patients (N = 115)	Sweden all patients (N = 340)	p-Value	Sudan matched patients (N = 88)	Sweden matched patients (N = 88)	p-Value
Sex (F/M)	110/5	297/40	0.02	85/3	79/9	0.07
Age at inclusion (years), median/mean	33/34.9	47.7/46.7	<0.0001	35/36.8	35.4/37.3	0.7
Any thrombosis	15 (13%)	77 (23.2%)	0.02	13 (14.8%)	14 (15.9%)	0.8
Venous thrombosis	8 (7%)	50 (15%)	0.03	7 (8%)	13 (14.8%)	0.1
Arterial thrombosis	10 (8.7%)	37 (11.1%)	0.5	9 (10.2%)	3 (3.4%)	0.07
Any obstetric event	37 (34.3%)	71 (26.9%)	0.1	31 (36.9%)	16 (23.2%)	0.06
Early miscarriage	19 (17%)	44 (15.8%)	0.8	18 (20.9%)	10 (13.5%)	0.2
Late miscarriage	18 (16.1%)	37 (13.2%)	0.5	14 (16.3%)	9 (12.2%)	0.4
IUFD/stillbirths	4 (3.7%)	7 (2.7%)	0.6	3 (3.6%)	1 (1.5%)	0.4
CVS	7 (6.1%)	33 (9.8%)	0.2	5 (5.7%)	1 (1.1%)	0.2

Sudanese and Swedish patients are compared both concerning the full cohorts as well as the nested group matched for age and disease duration. Significant differences are depicted in bold.

APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus; IUFD: intrauterine fetal demise; CVS: cardiovascular.

aPL profile

Sudanese SLE patients had higher levels of IgA and IgG aPL compared to Swedish patients. This finding was replicated with both assays, as depicted in Figures 1 and 2 and Table 2. Sudanese patients also had a significantly higher prevalence of IgA anti-β₂GPI using assay manufacturers’ suggested cut-offs common to both countries (FEIA: 34.8% vs. 14.9%, p<0.0001; PMAT 41.8% vs. 23%, p = 0.0004). Using the same cut-offs, IgA anti-β₂GPI was the most common antibody among SLE patients in both Sudan and Sweden (Table 2). Comparing control subjects from Sudan and Sweden, levels of IgA/IgG aCL and anti-β₂GPI were significantly higher among Sudanese subjects, irrespective of the assay used (Table 2). The percentage of controls testing positive for IgA anti-β₂GPI using manufacturers’ cut-offs was significantly higher among Sudanese compared to Swedish subjects (Figures 1(h) and 2(h)). By adjusting cut-offs to the 95th and 99th percentiles of national controls, this picture shifted so that Swedish patients now had a higher prevalence of IgA anti-β₂GPI, irrespective of assay used (Table 2). Also, using the calculated 99th national cut-off after exclusion of outlier values among controls, the increased prevalence of IgA aPL in Sudanese patients was lost. However, Sudanese patients showed higher IgM aPL positivity compared to Swedish patients (Table 2).

Figure 1.

Levels of IgA/G/M anticardiolipin (aCL) and anti-β₂ glycoprotein I (β₂GPI) analysed with fluorescence enzyme immunoassay among systemic lupus erythematosus (SLE) patients and controls. (a), (c) and (e) IgA/G/M aCL, and (b), (d) and (f) IgA/G/M anti-β₂GPI levels among Sudanese and Swedish SLE patients. Horizontal lines represent manufacturers’ cut-offs, the 95th and 99th percentile cut-off values of national controls, without exclusion of outliers. (g) and (h) IgA aCL and IgA anti-β₂GPI levels among Sudanese and Swedish controls. p-Values represent comparisons using the Mann–Whitney U-test for levels between patients ((a)–(f)) and the chi-square test for percentages between controls ((g) and (h)).

Figure 2.

Levels of IgA/G/M aCL and anti-β₂GPI analysed with particle-based multi-analyte technology among SLE patients and controls. (a), (c) and (e) IgA/G/M aCL and (b), (d) and (f) IgA/G/M anti-β₂GPI levels among Sudanese and Swedish SLE patients. Horizontal lines represent manufacturers’ cut-offs, the 95th and 99th percentile cut-off values of national controls, without exclusion of outliers. (g) and (h) IgA aCL and IgA anti-β₂GPI levels among Sudanese and Swedish controls. p-Values represent comparisons using the Mann–Whitney U-test for levels between patients ((a)–(f)), and chi-square test for percentages between controls ((g) and (h)).

Table 2.

Levels and prevalence of aCL and anti-β₂GPI isotypes among Sudanese and Swedish patients and controls.

	FEIA	FEIA		PMAT/CIA	PMAT/CIA
aPL in SLE patients	Sudan (N = 92)	Sweden (N = 311)	p-Value	Sudan (N = 93)	Sweden (N = 333)	p-Value
IgA CL, median/mean	6.5/10.3	4/7.2	<0.0001	194/304.9	148/315.3	<0.0001
IgG CL, median/mean	4.1/7.8	3/16.6	0.0002	205/442.9	190/873.8	0.09
IgM CL, median/mean	2.7/6.7	3.7/11.1	0.02	214/482.9	193/544.7	0.2
IgA β₂GPI, median/mean	6.3/20.8	2.7/8.8	<0.0001	212/452.3	118/268.2	<0.0001
IgG β₂GPI, median/mean	4.2/7.1	1.8/16.9	<0.0001	158/305.2	145.2/613	0.04
IgM β₂GPI, median/mean	2.0/5.6	1.4/9.6	0.006	146.2/406.6	132.5/425	0.09
β2GP1 D1 IgA, median/mean				1542/2301	1683/5147	0.045
IgA CL common cut-off	9 (9.8)	17 (5.8)	0.2	32 (35.2)	75 (22.7)	0.02
IgG CL common cut-off	4 (4.3)	21 (6.7)	0.4	14 (15)	72 (22.1)	0.1
IgM CL common cut-off	3 (3.2)	14 (4.5)	0.6	10 (11.4)	43 (13.1)	0.6
IgA β₂GPI common cut-off	32 (34.8)	43 (14.9)	<0.0001	38 (41.8)	76 (23)	0.0004
IgG β₂GPI common cut-off	10 (10.9)	44 (14.1)	0.4	5 (5.4)	50 (15.3)	0.01
IgM β₂GPI common cut-off	10 (10.9)	27 (8.7)	0.5	12 (13.6)	42 (12.9)	0.8
IgA β2GP1 DI common cut-off				6 (6.4)	38 (11.4)	0.2
IgA CL 95th cut-off	9 (9.8)	54 (18.6)	0.047	36 (39.6)	121 (26.6)	0.6
IgG CL 95th cut-off	8 (8.7)	42 (13.5)	0.2	24 (25.8)	103 (31.6)	0.3
IgM CL 95th cut-off	8 (8.7)	39 (12.5)	0.3	16 (18.2)	47 (14.4)	0.4
IgA β₂GPI 95th cut-off	18 (19.6)	100 (34.72)	0.006	20 (22)	125 (37.8)	0.005
IgG β₂GPI 95th cut-off	2 (2.1)	67 (21.5)	<0.0001	19 (20.4)	83 (25.5)	0.3
IgM β₂GPI 95th cut-off	14 (15.22)	57 (18.3)	0.5	20 (22.7)	57 (17.5)	0.3
IgA β2GP1 D1 95th cut-off				25 (26.9)	69 (20.7)	0.2
IgA CL 99th cut-off	7 (7.6)	21 (7.2)	0.9	7 (7.7)	31 (9.4)	0.6
IgG CL 99th cut-off	0 (0)	25 (8.0)	0.005	12 (12.9)	75 (23)	0.03
IgM CL 99th cut-off	1 (1.1)	15 (4.8)	0.1	10 (11.4)	24 (7.3)	0.2
IgA β₂GPI 99th cut-off	6 (6.5)	50 (17.4)	0.01	1 (1.1)	35 (10.6)	0.004
IgG β₂GPI 99th cut-off	0 (0)	15 (4.8)	0.03	3 (3.2)	56 (17.2)	0.0006
IgM β₂GPI 99th cut-off	9 (9.8)	22 (7.1)	0.4	12 (13.6)	33 (10.1)	0.3
IgA β2GP1 D1 99th cut-off				6 (6.4)	28 (8.4)	0.5
IgA CL 99th cut-off without outliers	7 (7.6)	21 (7.2)	0.9	23 (25.3)	86 (26)	0.8
IgG CL 99th cut-off without outliers	4 (4.3)	24 (7.9)	0.2	12 (12.9)	75 (23)	0.03
IgM CL 99th cut-off without outliers	1 (1.1)	15 (4.8)	0.1	13 (14.8)	24 (7.3)	0.03
IgA β₂GPI 99th cut-off without outliers	10 (10.9)	53 (18.4)	0.09	11 (12.1)	35 (10.6)	0.6
IgG β₂GPI 99th cut-off without outliers	1 (1.1)	17 (5.4)	0.07	19 (20.4)	65 (19.9)	0.9
IgM β₂GPI 99th cut-off without outliers	9 (9.8)	22 (7.1)	0.4	27 (30.6)	57 (17.5)	0.006
aPL in controls	Sudan (N = 106)	Sweden (N = 297)	p-Value	Sudan (N = 102)	Sweden (N = 163)	p-Value
IgA CL, median/mean	5.4/6.2	2.8/3.4	<0.0001	140/144	116/126	<0.0001
IgG CL, median/mean	4.7/7.2	2.8/4.2	<0.0001	170/184	157/166	0.01
IgM CL, median/mean	3.1/5.4	2.2/4.1	0.06	156/196	193/324	0.004
IgA β₂GPI, median/mean	3.4/6.8	1.5/1.9	<0.0001	105/169	83/94	<0.0001
IgG β₂GPI, median/mean	4.5/8.4	1.3/3	<0.0001	132/158	120/137.4	0.01
IgM β₂GPI, median/mean	2.3/2.6	0.7/1.2	<0.0001	100/130	114/177	0.1
IgA β2GP1 D1, median/mean				1132/1300	1439/1660	<0.0001

Occurrence of IgA/IgG/IgM aCL and anti-β₂GPI (n (%)) compared using three cut-offs: values recommended by the manufacturers and separate cut-offs based on the 95th and 99th percentiles among national controls. aCL and β₂GPI isotypes are measure with both FEIA and PMAT, and IgA anti-D1 was analysed with CIA; levels expressed as median/mean. Number of serum samples available for each assay is shown in the respective columns. Significant p-values are depicted in bold.

aCL: anticardiolipin antibodies; aPL: antiphospholipid antibodies; β₂ GPI: β₂ glycoprotein I; FEIA: fluorescence enzyme immunoassay; PMAT: particle-based multi-analyte technology; CIA: chemiluminescence assay; D1; domain 1.

In contrast to IgA anti-β₂GPI, both Swedish patients and controls exhibited higher levels of IgA anti-D1 compared to the corresponding Sudanese groups. The prevalence of IgA anti-D1 did not differ between Sudanese and Swedish patients, regardless of cut-offs (Table 2).

Levels obtained with the FEIA and PMAT correlated strongly for all investigated aPL and with similar figures for Sudanese and Swedish patients (Spearman’s ρ = 0.47–0.83 for all patients). For each immunoglobulin isotype, the degree of correlation was always stronger for anti-β₂GPI than for aCL, and for each specificity, the degree of correlation was highest for IgA aPL followed by IgM and IgG. The highest degree of correlation was found for IgA anti-β₂GPI (ρ = 0.83).

Clinical associations with aPL

Sudanese patients

None of the aPL associated with venous or arterial thrombotic events, whereas CVS events associated with IgG aCL (p = 0.04) and IgM anti-β₂GPI (p = 0.01). Early miscarriage was more prevalent among IgM aCL and IgM anti-β₂GPI-positive patients (p = 0.005 and p = 0.03), while a history of IUFD/stillbirths was only associated with IgM anti-β₂GPI (p = 0.04). A history of ITP was more common in IgA anti-D1 positive compared to negative patients (p = 0.004). Patients with thrombocytopaenia at study inclusion were few (n = 2), and no associations to any aPL were observed (data not shown). Adjusting aPL cut-offs to national controls increased autoantibody associations to adverse pregnancy outcomes and exclusively showed an association with ITP (Supplemental Table S1).

Swedish patients

In contrast to Sudanese patients, aPL in general were associated with thrombotic events in the full cohorts (Supplemental Table S2). Venous thrombosis was more common among patients positive for most measures of IgG aPL and many measures of IgA aPL, including IgA anti-D1 autoantibodies. On the other hand, arterial thrombosis was associated only with IgA anti-D1 (p = 0.008). IgG aCL were associated with early and late miscarriages as well as cardiovascular events (p = 0.03, p = 0.02 and p = 0.03, respectively), whereas IgA isotypes of all aPL were associated with stillbirth. Thrombocytopaenia was more common in IgA/IgG aCL and anti-β₂GPI-positive patients. In contrast to evaluations using manufacturers’ cut-offs, adjustment to the 95th national percentile showed positive aPL associations with miscarriage and stillbirths (Supplemental Table S2). In the matched Swedish cohort where the number of patients was much lower, most aPL associations with thromboses were lost and remained only for venous thrombosis and IgG aCL (p = 0.02) and IgG anti-β₂GPI (p = 0.048; data not shown).

Discussion

In this study, we investigated and compared the prevalence and clinical significance of aCL and β₂GPI isotypes among SLE patients from Sudan and Sweden applying analogous methodology including assays and cut-offs used.

We detected that high IgA aPL levels and positivity was common among Sudanese patients using manufacturers’ cut-offs. Intriguingly, levels were also higher among Sudanese compared to Swedish controls, and when using nationally adjusted cut-offs, this difference disappeared. In some comparisons, Swedish patients instead showed an increased prevalence of IgA aPL, most evident for IgA anti-β₂GPI.

It is consistently reported that IgA anti-β₂GPI antibodies are the most commonly occurring aPL in SLE patients with African ancestry.²,⁴,¹⁹,²⁹ In contrast to our current study methodology, all previous studies on aPL in SLE among African populations have either used common manufacturers’ cut-offs, most probably based on Caucasian controls, or have adjusted cut-offs based on parametric statistics assuming normal distribution of aPL levels. As our data were non-normally distributed, and as non-parametric determination of aPL cut-offs was recommended by the latest Sapporo criteria for APS diagnosis⁷ as well as the International Task Force on the 14th aPL Congress on Laboratory Diagnostics and Trends,²¹ we regard our approach of adjusting cut-offs to age- and sex-matched national controls as a strength of the current study. Indeed, this approach revealed a different picture compared to commonly used manufacturers’ cut-offs (Table 2).

In our recently published paper on 120 healthy pregnant women from Sudan, markedly increased IgA aPL levels and prevalence were observed compared to non-pregnant controls. This finding was not seen in Swedish healthy pregnancies and was not accompanied by a parallel increase in IgA anti-D1.²⁵ Moreover, in a former study on 89 Tunisian patients with inflammatory bowel diseases, a high prevalence of IgA anti-β₂GPI, adjusted for total IgA, was reported using the 95th percentile of national controls.³⁰ A similarly high prevalence of IgA anti-β₂GPI was also reported in primary biliary cirrhosis patients from the same country.³¹ Therefore, from these studies, our current study and previously published data, we speculate that increased occurrence of IgA aPL, most clearly shown for anti-β₂GPI, may be a propensity not only in Sudan but also in other regions of North Africa. We believe that the increased level of IgA aPL is not limited to SLE patients but rather is a general phenomenon seen in both healthy and diseased Sudanese subjects. Detection of IgA aPL has also been reported in non-APS conditions (e.g. metabolic, renal and infectious diseases).^32–34 An association with infections was shown since the early description of aCL antibodies.³⁵,³⁶ Given the fact that infection is also considered as one of the possible second hits triggering APS, it is difficult to consider infection-induced aPL as totally innocent. The increased IgA aPL levels in African populations might reflect mucosal immunity and/or molecular cross-reactivity with infectious agents. Conventionally speaking, infection-related aPL should mostly react with the cardiolipin moiety (and not with the added co-factors), but an increase in anti-β₂GPI was also reported in South African patients with viral and parasitic infections.³⁷ Therefore, further investigations of antibodies against individual domains of β₂GPI or other pathogenic ‘non-criteria’ aPL could be of value in these populations.

Occurrence of IgA anti-D1 antibodies did not differ between Sudanese and Swedish SLE patients, and thus the increased IgA reactivity to β₂GPI in Sudanese individuals was not primarily against the D1 epitope. Our current data are, on the other hand, in agreement with our recent report showing an increase in IgA anti-β₂GPI but not in IgA anti-D1 among healthy pregnant women in Sudan.²⁵ IgG anti-D1 is consistently reported to be accountable for APS-related events.³⁸,³⁹ However, data on the significance of IgA/IgM isotypes are deficient. Despierres et al. previously showed that IgA anti-domain 4/5 and not IgA anti-D1 are associated with SLE.⁴⁰ In a recent study by Serrano et al., APS patients with thrombosis more often had IgA antibodies against β₂GPI domains 3, 4 and 5 than they had IgA anti-D1.⁴¹ These findings conformed to an earlier study by Blank et al., showing that three peptides interfering with binding of monoclonal antibodies against domains 1 and 2, 3 and 4 prevented the development of experimental APS.⁴² In our study, neither IgA anti-β₂GPI nor IgA anti-D1 associated with thrombotic or obstetric events among Sudanese patients. It is, however, difficult to determine whether this is a true negative finding or due to low statistical power. We are currently planning further investigations for IgA anti-domain 4/5 and IgG anti-D1 in Sudanese and Swedish cohorts.

IgA anti-β₂GPI was found to be the most common isotype in SLE patients both in Sudan and Sweden using manufacturers’ cut-offs. In a recent paper investigating 526 Swedish SLE patients, and where our currently investigated Swedish patients were included, aPL cut-offs were adjusted to the 99th percentile value of 507 controls. IgA anti-β₂GPI was found to be the most frequent aPL, irrespective of the co-occurrence of other isotypes, and significantly associated with non-Caucasian origin.⁶ In our current study, isolated IgA anti-β₂GPI was not associated with any clinical event in Sudan or Sweden (data not shown). This is in contrast to an earlier study on 198 patients who tested positive for IgA anti-β₂GPI recruited from three multi-ethnic cohorts where around 40% of participants were African Americans: the ‘Lupus in Minorities: Nature vs. Nurture’ (LUMINA) cohort, the Hopkins Lupus cohort and the Antiphospholipid Standardization laboratory cohort. In that study, isolated IgA antibodies were associated with arterial as well as any thromboses.⁴³

Despite the inclusion of IgA aPL isotypes in the recent SLE classification criteria,⁹ there is yet no strong evidence relating these antibodies to thrombotic and/or pregnancy morbidity risk.⁷,²¹ We investigated aPL associations with APS-related clinical events using the common conventional and the adjusted cut-offs to the 95th percentiles of national controls. We determined the small number of Sudanese controls (n = 106) to be insufficient to determine the 99th percentile cut-offs accurately for such clinical comparisons,⁴⁴ and used two independent ways to determine the 99th percentile for comparing the occurrence of aPL in Sudan and Sweden. For both countries, the 95th national cut-offs, compared to manufacturers’ cut-offs, showed more aPL associations to adverse pregnancy outcomes (Supplemental Tables S1 and S2). This might be of special interest, as it is concordant to previous reports where low-titre aPL (>95th and <99th) were clinically significant as risk factors for pregnancy morbidity in APS.⁴⁵,⁴⁶

Sudanese SLE patients had fewer venous thrombosis events compared to Swedish patients. However, when matching the cohorts for age and disease duration, this difference was lost. It is noteworthy that a patient history of arterial and/or venous thrombosis was not associated with any aPL in Sudanese patients, in contrast to Swedish patients. Nevertheless, most aPL associations with thrombosis were also lost in the matched Swedish patients, probably due to there being fewer subjects and thus a loss of statistical power. A new study presented at the 2019 ACR/ARP annual meeting, showed that African American SLE patients with venous thrombosis are 66% less likely to have a significant aPL profile compared to Caucasian patients.⁴⁷ Therefore, negative aPL in African American SLE patients does not seem to exclude the risk of thrombosis. However, IgA aPL were not investigated in this study. The lack of an association of aPL with thrombosis in Sudanese patients might be in part due to the small number of events and/or aPL fluctuations over time.^48–50 In our study, history of thrombosis was collected retrospectively from patients’ records. Levels of aPL have been previously shown to drop as a result of hydroxychloroquine (HCQ) treatment.⁵¹,⁵² In the current study, 9/15 (60%) Sudanese patients with thrombosis had ongoing treatment with HCQ compared to 22/77 (30%) Swedish patients (p = 0.02; data not shown). The common use of HCQ among Sudanese patients might also help to explain the lower prevalence of thrombosis compared to Swedish patients due to the preventive effect of this treatment.⁵³

Limitations to this study are the cross-sectional approach where persistence of aPL was not investigated, and the limited number of Sudanese controls to calculate 99th percentile cut-offs accurately.

To the best of our knowledge, this is the first study designed to investigate aPL in SLE among Africans living in Northern Africa and also comparing to Caucasian populations using a similar methodological approach including national adjustment of reference ranges. The findings of high levels of IgA anti-β₂GPI among Sudanese SLE patients as well as healthy controls compared to Swedes, together with the striking change in IgA aPL occurrence when adjusting to national reference ranges, have not been described before in patients of African origin. Our findings suggest that previous studies demonstrating a high IgA aPL prevalence might be re-evaluated using similar approaches.

Supplemental Material

sj-pdf-1-lup-10.1177_0961203320945387 - Supplemental material for High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

Supplemental material, sj-pdf-1-lup-10.1177_0961203320945387 for High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients by Sahwa Elbagir, Amir I Elshafie, Elnour M Elagib, NasrEldeen A Mohammed, Mawahib IE Aledrissy, Vivek Anand Manivel, Eleftheria Pertsinidou, Musa AM Nur, Iva Gunnarsson, Elisabet Svenungsson and Johan Rönnelid in Lupus

Footnotes

Acknowledgements

We thank Maryam Poorafshar at Thermo Fisher Scientific and Silvia Casas and Michael Mahler at Inova Diagnostics who provided both laboratory reagents, access to assay equipment and manpower for autoantibody analyses.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the Swedish Rheumatism Association; King Gustav Vth 80-year foundation; the Agnes and Mac Rudberg Foundation; the Signe and Reinhold Sund’s Foundation for Rheumatological Research; Ingegerd Johansson´s foundation (SLS-713911); the Swedish Research Council; the Uppsala County Council (ALF); the Stockholm County Council (ALF); and the Swedish Heart-Lung Foundation.

ORCID iD

Sahwa Elbagir

Supplemental material

Supplemental material for this article is available online.

References

Vikerfors

Johansson

Gustafsson

, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 2013; 52: 501–509.

Cucurull

Gharavi

Diri

Mendez

Kapoor

Espinoza

LR.

IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999; 318: 55–60.

Samarkos

Davies

Gordon

Loizou

Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.

Clin Rheumatol 2006; 25: 199–204.

Mehrani

Petri

Association of IgA anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus.

J Rheumatol 2011; 38: 64–68.

Andreoli

Fredi

Nalli

, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. Curr Rheumatol Rep 2013; 15: 343.

Frodlund

Vikerfors

Grosso

, et al. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clin Exp Immunol 2018; 194: 27–38.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Petri

Orbai

Alarcón

, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Aringer

Costenbader

Daikh

, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151–1159.

10.

Molina

Gutierrez-Ureña

Molina

, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 291–296.

11.

Fanopoulos

Teodorescu

Varga

Teodorescu

High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998; 25: 675–680.

12.

Tsutsumi

Matsuura

Ichikawa

Fujisaku

Mukai

Koike

IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 74–78.

13.

Lee

Cho

Joo

, et al. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 520–524.

14.

Bruce

Clark-Soloninka

Spitzer

Gladman

Urowitz

Laskin

CA.

Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol 2000; 27: 2833–2837.

15.

Bertolaccini

Atsumi

Escudero Contreras

Khamashta

Hughes

GR.

The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001; 28: 2637–2643.

16.

Martínez-Flores

Serrano

Alfaro

, et al. Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal Chem 2013; 85: 12093–12098.

17.

Perez

Martínez-Flores

Serrano

, et al. Evaluation of three fully automated immunoassay systems for detection of IgA anti-beta 2-glycoprotein I antibodies. Int J Lab Hematol 2016; 38: 560–568.

18.

Tebo

Willis

Jaskowski

, et al. Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. Clin Chim Acta 2016; 460: 107–113.

19.

Diri

Cucurull

Gharavi

, et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999; 8: 263–268.

20.

Gould

Tikly

Asherson

Loizou

Singh

Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29–34.

21.

Bertolaccini

Amengual

Andreoli

, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13: 917–930.

22.

Tan

Cohen

Fries

, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

23.

Elbagir

Elshafie

Elagib

, et al. Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. Rheumatology (Oxford) 2020; 59: 968–978.

24.

Gladman

Ginzler

Goldsmith

, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

25.

Elbagir

Mohammed

Kaihola

, et al. Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-β2 glycoprotein I domain 1 antibodies. Lupus 2020; 29: 463–473.

26.

Pengo

Tripodi

Reber

, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

27.

Dixon

WJ.

Processing data for outliers. Biometrics 1953; 9: 74–89.

28.

Reed

Henry

Mason

WB.

Influence of statistical method used on the resulting estimate of normal range.

Clin Chem 1971; 17: 275–284.

29.

Danowski

Kickler

Petri

Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006; 33: 1775–1779.

30.

Kraiem

Hadhri

Ben Rejeb

, et al. Antiphospholipid antibodies and procoagulant profile in Tunisians with inflammatory bowel diseases. Clin Appl Thromb Hemost 2016; 22: 734–742.

31.

Mankaï

Manoubi

Ghozzi

Melayah

Sakly

Ghedira

High frequency of antiphospholipid antibodies in primary biliary cirrhosis. J Clin Lab Anal 2015; 29: 32–36.

32.

Asherson

Cervera

Antiphospholipid antibodies and infections.

Ann Rheum Dis 2003; 62: 388–393.

33.

Borges

Bodanese

Mühlen

, et al. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arq Bras Cardiol 2011; 96: 272–276.

34.

Serrano

García

Serrano

, et al. IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int 2012; 81: 1239–1244.

35.

Harris

Gharavi

Boey

, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211–1214.

36.

Michaelis

Precipitin reaction bei syphilis. Berl Klin Wochenschr 1907; 44: 1635–1645.

37.

Loizou

Singh

Wypkema

Asherson

RA.

Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.

Ann Rheum Dis 2003; 62: 1106–1111.

38.

De Laat

Derksen

Urbanus

De Groot

PG.

IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.

Blood 2005; 105: 1540–1545.

39.

Mahler

Norman

Meroni

Khamashta

Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome.

Autoimmun Rev 2012; 12: 313–317.

40.

Despierres

Beziane

Kaplanski

, et al. Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. Rheumatology (Oxford) 2014; 53: 1215–1218.

41.

Serrano

Martinez-Flores

Norman

Naranjo

Morales

Serrano

The IgA isotype of anti-β2 glycoprotein I antibodies recognizes epitopes in domains 3, 4, and 5 that are located in a lateral zone of the molecule (L-shaped).

Front Immunol 2019; 10: 1031.

42.

Blank

Shoenfeld

Cabilly

Heldman

Fridkin

Katchalski-Katzir

Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

Proc Natl Acad Sci U S A 1999; 96: 5164–5168.

43.

Murthy

Willis

Romay-Penabad

, et al. Value of isolated IgA anti-β2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: 3186–3193.

44.

Devreese

Pierangeli

De Laat

Tripodi

Atsumi

Ortel

TL.

Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH.

J Thromb Haemost 2014; 12: 792–795.

45.

Boffa

Boinot

De Carolis

, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost 2009; 102: 25–28.

46.

Gardiner

Hills

Machin

Cohen

Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013; 22: 18–25.

47.

Gkrouzman

Davis-Porada

Peng

Kirou

Presence of antiphospholipid antibodies in patients with SLE and venous thromboembolic events of African American and Caucasian race [abstract].

Arthritis Rheumatol 2019 ; 71.

48.

Riancho-Zarrabeitia

Daroca

Muñoz

López-Hoyos

Haya

Martínez-Taboada

VM.

Serological evolution in women with positive antiphospholipid antibodies.

Semin Arthritis Rheum 2017; 47: 397–402.

49.

Alarcón-Segovia

Delezé

Oria

, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353–365.

50.

Out

Van Vliet

De Groot

Derksen

RH.

Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.

Ann Rheum Dis 1992; 51: 353–357.

51.

Broder

Putterman

Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.

J Rheumatol 2013; 40: 30–33.

52.

Nuri

Taraborelli

Andreoli

, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017; 65: 17–24.

53.

Petri

Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Curr Rheumatol Rep 2011; 13: 77–80.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB